FibroGen, Inc.
FGEN
$0.2912
-$0.0269-8.46%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 156.01M | 79.07M | 72.87M | 66.54M | 46.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 156.01M | 79.07M | 72.87M | 66.54M | 46.80M |
| Cost of Revenue | 131.46M | 180.90M | 219.34M | 281.24M | 295.07M |
| Gross Profit | 24.56M | -101.84M | -146.47M | -214.70M | -248.27M |
| SG&A Expenses | 71.00M | 58.10M | 66.12M | 75.03M | 86.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 202.45M | 239.01M | 285.46M | 356.27M | 381.56M |
| Operating Income | -46.44M | -159.94M | -212.60M | -289.72M | -334.75M |
| Income Before Tax | -74.44M | -160.92M | -207.38M | -279.49M | -323.22M |
| Income Tax Expenses | -215.00K | -392.00K | -320.00K | -293.00K | -252.00K |
| Earnings from Continuing Operations | -74.23 | -160.53 | -207.06 | -279.20 | -322.97 |
| Earnings from Discontinued Operations | 26.65M | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.58M | -121.79M | -168.32M | -240.46M | -284.23M |
| EBIT | -46.44M | -159.94M | -212.60M | -289.72M | -334.75M |
| EBITDA | -43.75M | -155.73M | -206.74M | -281.94M | -324.82M |
| EPS Basic | -0.48 | -1.23 | -1.70 | -2.45 | -2.92 |
| Normalized Basic EPS | -0.35 | -1.06 | -1.39 | -1.86 | -2.15 |
| EPS Diluted | -0.48 | -1.23 | -1.70 | -2.45 | -2.92 |
| Normalized Diluted EPS | -0.35 | -1.06 | -1.39 | -1.86 | -2.15 |
| Average Basic Shares Outstanding | 400.16M | 396.64M | 394.37M | 392.26M | 387.97M |
| Average Diluted Shares Outstanding | 400.16M | 396.64M | 394.37M | 392.26M | 387.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |